Skip to main content

English
Français

Oncology Resource Hub

HELPFUL INFORMATION AT YOUR FINGERTIPS

Oncology Resource Hub

Click a brand below for quick access to its library of tools.

Rylaze
Vyxeos
Defitelio

^PrVYXEOS^®

Vyxeos_Detail aid

Vyxeos_Dose guide

Vyxeos_HCP leave behind

Vyxeos_HCP website

Vyxeos_Made in Canada leave-behind

Vyxeos Made in Canada

Vyxeos

Vyxeos_PM

Vyxeos Reconstitution

Vyxeos_Patient brochure

CA-DEF-2400006E | September 2024

This site is intended for Canadian Healthcare Practitioners Only.

Rylaze (crisantaspase recombinant) is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase.

VYXEOS (daunorubicin and cytarabine liposome for injection) is indicated for treatment of adults with newly diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

DEFITELIO (defibrotide sodium) solution for intravenous infusion is indicated for the treatment of adult and pediatric patients with severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following haematopoietic stem-cell transplantation (HSCT).

Consult the respective product monographs for contraindications, serious warnings and precautions, adverse reactions, interactions, dosing, and conditions of clinical use: here for Rylaze, here for VYXEOS and here for DEFITELIO. The Product Monographs are also available by calling 1-800-520-5568.

Image

Logo_JazzPharma_White

Footer menu

Terms of use
Privacy statement
Contact us
Cookie Policy

© 2024 Jazz Pharmaceuticals, Inc. All rights reserved.
CA-VYX-2400061E | September 2024

Download Successfully

Thanks for downloading